Vanguard Capital Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Hold	530	–	–	0.18%	103
2026 Q1	$237K	Hold	530	–	–	0.22%	91
2025 Q4	$240K	Hold	530	–	–	0.19%	104
2025 Q3	$208K	Sell	530 -30	-5%	-$12.5K	0.17%	121
2025 Q2	$249K	Hold	560	–	–	0.25%	86
2025 Q1	$271K	Sell	560 -5	-0.9%	-$2.33K	0.33%	70
2024 Q4	$228K	Sell	565 -90	-14%	-$41.7K	0.25%	86
2024 Q3	$305K	Sell	655 -185	-22%	-$88.9K	0.32%	69
2024 Q2	$394K	Hold	840	–	–	0.27%	80
2024 Q1	$351K	Buy	840 +10	+1%	+$4.23K	0.25%	82
2023 Q4	$338K	Sell	830 -240	-22%	-$88.7K	0.27%	80
2023 Q3	$372K	Buy	1,070 +190	+22%	+$66.4K	0.34%	69
2023 Q2	$310K	Hold	880	–	–	0.28%	76
2023 Q1	$277K	Hold	880	–	–	0.28%	81
2022 Q4	$254K	Buy	880 +80	+10%	+$24.4K	0.29%	83
2022 Q3	$232K	Buy	+800	New	+$230K	0.28%	81

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Capital Wealth Advisors's VRTX Position: Q2 2026 in Review

Vanguard Capital Wealth Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 530 shares worth $263K. The position accounts for 0.18% of the portfolio, ranked #103.

Vanguard Capital Wealth Advisors first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $394K in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Vanguard Capital Wealth Advisors held 530 shares of Vertex Pharmaceuticals worth $263K as of Q2 2026.
Vanguard Capital Wealth Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.18% of Vanguard Capital Wealth Advisors's portfolio in Q2 2026, its #103 holding.
Vanguard Capital Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
Vanguard Capital Wealth Advisors's Vertex Pharmaceuticals position peaked at $394K in Q2 2024.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.